Broadfin Capital LLC Boosted Stake in Adamas Pharmaceuticals INC (ADMS) as Market Valuation Declined

Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) Logo

Broadfin Capital Llc increased its stake in Adamas Pharmaceuticals Inc (ADMS) by 24.83% based on its latest 2018Q2 regulatory filing with the SEC. Broadfin Capital Llc bought 281,918 shares as the company’s stock declined 17.64% while stock markets rallied. The hedge fund held 1.42 million shares of the health care company at the end of 2018Q2, valued at $36.60M, up from 1.14M at the end of the previous reported quarter. Broadfin Capital Llc who had been investing in Adamas Pharmaceuticals Inc for a number of months, seems to be bullish on the $272.81M market cap company. The stock decreased 0.30% or $0.03 during the last trading session, reaching $9.98. About 412,860 shares traded. Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) has risen 9.07% since December 8, 2017 and is uptrending. It has underperformed by 6.55% the S&P500.

Broadfin Capital Llc, which manages about $1.26 billion and $635.22 million US Long portfolio, decreased its stake in Mirati Therapeutics Inc (NASDAQ:MRTX) by 423,770 shares to 1.02M shares, valued at $50.30M in 2018Q2, according to the filing. It also reduced its holding in Retrophin Inc (NASDAQ:RTRX) by 129,533 shares in the quarter, leaving it with 1.05 million shares, and cut its stake in Integra Lifesciences Hldgs C (NASDAQ:IART).

More notable recent Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) news were published by: which released: “Premarket analyst action – healthcare – Seeking Alpha” on October 05, 2018, also with their article: “Adamas Announces New Employment Inducement Grant Nasdaq:ADMS – GlobeNewswire” published on October 05, 2018, published: “Adamas Pharmaceuticals: Interesting Over The Long Term – Seeking Alpha” on May 18, 2018. More interesting news about Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) were released by: and their article: “Adamas Pharma operating chief bids adieu – Seeking Alpha” published on September 14, 2018 as well as‘s news article titled: “Adamas Pharma down 10% on Gocovri headwinds – Seeking Alpha” with publication date: October 05, 2018.

Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) Ratings Coverage

Among 4 analysts covering Adamas Pharmaceuticals (NASDAQ:ADMS), 2 have Buy rating, 0 Sell and 2 Hold. Therefore 50% are positive. Adamas Pharmaceuticals had 5 analyst reports since June 22, 2018 according to SRatingsIntel. The rating was downgraded by Bank of America to “Neutral” on Friday, October 5. The rating was maintained by Mizuho with “Buy” on Friday, June 22. Mizuho downgraded the shares of ADMS in report on Monday, November 5 to “Neutral” rating.

Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.